Prophase Labs (PRPH)
OTHER OTC:PRPH
Want to see PRPH full AI Analyst Report?
PRPH Stock Chart & Stats
$0.18
-$0.13(-18.06%)
At close: 4:00 PM EST
$0.18
-$0.13(-18.06%)
Day’s Range― - ―
52-Week Range$0.07 - $6.66
Previous CloseN/A
Volume469.10K
Average Volume (3M)47.62K
Market Cap
$759.46K
Enterprise Value$7.75M
Total Cash (Recent Filing)$90.00K
Total Debt (Recent Filing)$8.62M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.47
Shares Outstanding9,493,287
10 Day Avg. Volume88,383
30 Day Avg. Volume47,622
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.09
Price to Sales (P/S)0.88
P/FCF Ratio-0.43
Enterprise Value/Market Cap10.21
Enterprise Value/Revenue1.78
Enterprise Value/Gross Profit5.60
Enterprise Value/Ebitda-0.84
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)10.4
Revenue Forecast (FY)$41.69M
Bulls Say, Bears Say
Bulls Say
Diversified Revenue StreamsProPhase operates two distinct revenue channels—OTC consumer products and clinical diagnostics—which provides structural diversification. This dual model reduces dependence on a single market cycle, supports multiple pricing and reimbursement drivers, and gives management alternate cash funnels over the medium term.
Operational Improvement In 2025Reported margin improvement and narrower losses in 2025 indicate management has begun to stabilize operations. Sustained margin recovery can compound into durable profitability if execution continues, improving cash conversion and reducing the probability of repeat restructuring or acute liquidity events.
Debt Reduction In 2025A decline in total debt demonstrates progress toward reducing financial strain and interest burden. Even if leverage stays high, lower absolute debt improves near-term flexibility, reduces refinancing needs, and provides a firmer base for reinvesting in growth or sustaining operations over the coming months.
Bears Say
Multi-year Negative Cash FlowSustained negative operating and free cash flow over multiple years is a structural risk: it forces reliance on external financing, constrains reinvestment, and raises dilution or default risk. Without durable cash-generation improvements, funding needs could limit strategic options over months.
Elevated Leverage And Eroded EquityHigher leverage coupled with sharply reduced equity reduces the company’s capital cushion and increases vulnerability to revenue shocks. Elevated debt levels limit flexibility for M&A or capex, increase refinancing risk, and amplify downside over a multi-month horizon if earnings remain weak.
Volatile Revenue And Weak ProfitabilityLarge revenue swings and past negative gross margins indicate unstable demand or cost structure issues. Persistent operating and net losses undermine the ability to plan and scale, complicate partner and payor contracts, and make consistent margin recovery uncertain over the medium term.
Prophase Labs News
PRPH FAQ
What was Prophase Labs’s price range in the past 12 months?
Prophase Labs lowest stock price was $0.07 and its highest was $6.66 in the past 12 months.
What is Prophase Labs’s market cap?
Prophase Labs’s market cap is $759.46K.
When is Prophase Labs’s upcoming earnings report date?
Prophase Labs’s upcoming earnings report date is Aug 06, 2026 which is in 52 days.
How were Prophase Labs’s earnings last quarter?
Currently, no data Available
Is Prophase Labs overvalued?
According to Wall Street analysts Prophase Labs’s price is currently Overvalued.
Does Prophase Labs pay dividends?
Prophase Labs pays a Quarterly dividend of $0.3 which represents an annual dividend yield of N/A. See more information on Prophase Labs dividends here
What is Prophase Labs’s EPS estimate?
Prophase Labs’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prophase Labs have?
Prophase Labs has 9,493,287 shares outstanding.
What happened to Prophase Labs’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Prophase Labs?
Currently, no hedge funds are holding shares in PRPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Prophase Labs
ProPhase Labs, Inc., founded in 1989 in Garden City, New York (and previously known as The Quigley Corporation), operates as a diversified company with two main areas of focus: Consumer Products and Diagnostic Services. Through its Consumer Products division, ProPhase Labs is actively involved in the entire process—from researching and developing to manufacturing, distributing, marketing, and selling—a range of over-the-counter (OTC) healthcare items and nutritional supplements within the United States. Notable offerings include dietary supplements like Legendz XL, which supports male sexual health, and Triple Edge XL, formulated to enhance energy and stamina. The Diagnostic Services segment provides crucial testing solutions, including PCR tests for SARS-CoV-2 (COVID-19) and its variant mutations, using both saliva and nasal swab collection methods. This segment also offers molecular testing for other respiratory pathogens and supplies personal genomics products and services. Additionally, ProPhase Labs extends its capabilities by providing comprehensive contract manufacturing services, covering product development, pre-commercialization activities, production, warehousing, and distribution. The company's diverse products and services reach consumers through a broad network of national chain drug stores, various regional retailers, and online platforms.
Technical Analysis
Ownership Overview
37.75%
Insiders
0.23% Mutual Funds
0.89% Other Institutional Investors
61.13% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---